Purchasing factor concentrates in the 21st century through competitive tendering

Haemophilia

Volumn 19, Issue 5, 2013, Pages 660-667

  Hay, C R M ^a,b  

^a National Haemophilia Database   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Competitive tendering; Factor concentrates; Purchasing

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 8;

DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; REVIEW;

COMPETITIVE TENDERING; FACTOR-CONCENTRATES; PURCHASING;

BLOOD COAGULATION FACTORS; COMPETITIVE BIDDING; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HEMOPHILIA A; HUMANS; STATE MEDICINE;

EID: 84883049423     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12169     Document Type: Review

References (12)

1. Ludlam CA, Colvin BT, Hay CRM, Lee CA, Dolan G, The UKHCDO Therapeutics Guidelines Task-Force on behalf of the UKHCDO Executive Committee. Guidelines on the use of therapeutic products to treat haemophilia and other hereditary coagulation disorders (2nd edition). Haemophilia 1997; 3: 63-77.
2. Gouw SC, Van der Bom JG, Ljung R et al., for the PedNet and Rodin Study Group Factor VIII products and inhibitor development in severe hemophilia A. NEJM 2013; 368: 231-9.
3. Hay CRM, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
4. Hay CRM, Palmer B, Chalmers E et al., on behalf of UKHCDO. The incidence of factor VIII inhibitors in severe haemophilia A following a major product switch in the UK: a prospective, controlled study. Haemophilia 2012; 18: 828.
5. Hay CRM, Palmer B, Dewhurst L. UK Bleeding Disorder Statistics for 2011/12. In UKHCDO Annual Report 2012 © UKHCDO 2012.
6. Sharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001; 7: 766.
7. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-148.
8. Rubinger M, Lillicrap D, Rivard GE et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian hemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14: 281-286.
9. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-92.
10. Iorio A, Marcucci M, Makris M. Concentrate-related inhibitor risk: is a diference always real? J Thromb Haemost 2011; 9: 2176-9.
11. Aledort LM, Navickis RJ, Wilkes MM. Best evidence of B-domain deletion and the immunogenicity of recombinant factor VIII. J Thromb Haemost 2011; 9: 2325-7.
12. Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 2012; 120: 720-7.